NOX 0.00% 12.0¢ noxopharm limited

Ann: New Independent Trial Data Supports Potential of Veyonda, page-36

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 6,851 Posts.
    lightbulb Created with Sketch. 2536
    Not sure what happened there but the links and ref are missing. But you get the point. The invention year was 2012. This is just another non-final action rejection which has a successful grant extension time on it. So not over by far yet. But my point is the amount of time it is taken to nail these down should be concern to any investor.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.